TR200704553T2 - Streptokok antijenleri. - Google Patents
Streptokok antijenleri.Info
- Publication number
- TR200704553T2 TR200704553T2 TR2007/04553T TR200704553T TR200704553T2 TR 200704553 T2 TR200704553 T2 TR 200704553T2 TR 2007/04553 T TR2007/04553 T TR 2007/04553T TR 200704553 T TR200704553 T TR 200704553T TR 200704553 T2 TR200704553 T2 TR 200704553T2
- Authority
- TR
- Turkey
- Prior art keywords
- streptococcal
- polypeptides
- streptococcal antigens
- animals
- prevention
- Prior art date
Links
- 102000036639 antigens Human genes 0.000 title abstract 2
- 108091007433 antigens Proteins 0.000 title abstract 2
- 239000000427 antigen Substances 0.000 title 1
- 229920001184 polypeptide Polymers 0.000 abstract 2
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 2
- 241001465754 Metazoa Species 0.000 abstract 1
- 206010061372 Streptococcal infection Diseases 0.000 abstract 1
- 241000194017 Streptococcus Species 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 102000040430 polynucleotide Human genes 0.000 abstract 1
- 108091033319 polynucleotide Proteins 0.000 abstract 1
- 239000002157 polynucleotide Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 238000010188 recombinant method Methods 0.000 abstract 1
- 229960005486 vaccine Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Communicable Diseases (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Oncology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Pulmonology (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physics & Mathematics (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Plant Pathology (AREA)
- Gastroenterology & Hepatology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US21268300P | 2000-06-20 | 2000-06-20 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TR200704553T2 true TR200704553T2 (tr) | 2007-11-21 |
Family
ID=22792041
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TR2007/04553T TR200704553T2 (tr) | 2000-06-20 | 2001-06-19 | Streptokok antijenleri. |
Country Status (18)
| Country | Link |
|---|---|
| EP (2) | EP1303612A2 (enExample) |
| JP (2) | JP5051959B2 (enExample) |
| KR (1) | KR100927767B1 (enExample) |
| CN (2) | CN101260149B (enExample) |
| AR (1) | AR033980A1 (enExample) |
| AU (2) | AU7038101A (enExample) |
| CA (1) | CA2413450C (enExample) |
| CZ (1) | CZ2003154A3 (enExample) |
| EA (1) | EA006232B1 (enExample) |
| HU (1) | HU228706B1 (enExample) |
| IL (2) | IL153558A0 (enExample) |
| MX (1) | MXPA03000103A (enExample) |
| NO (1) | NO331103B1 (enExample) |
| NZ (1) | NZ553554A (enExample) |
| PL (1) | PL214229B1 (enExample) |
| TR (1) | TR200704553T2 (enExample) |
| UY (1) | UY26783A1 (enExample) |
| WO (1) | WO2001098334A2 (enExample) |
Families Citing this family (76)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7128918B1 (en) | 1998-12-23 | 2006-10-31 | Id Biomedical Corporation | Streptococcus antigens |
| US7074415B2 (en) | 2000-06-20 | 2006-07-11 | Id Biomedical Corporation | Streptococcus antigens |
| AU2002351623A1 (en) | 2001-12-20 | 2003-07-09 | Shire Biochem Inc. | Streptococcus antigens |
| TWI457133B (zh) | 2005-12-13 | 2014-10-21 | Glaxosmithkline Biolog Sa | 新穎組合物 |
| PL3017827T3 (pl) | 2005-12-22 | 2019-04-30 | Glaxosmithkline Biologicals Sa | Szczepionka z koniugatem polisacharydu pneumokokowego |
| GB0607088D0 (en) | 2006-04-07 | 2006-05-17 | Glaxosmithkline Biolog Sa | Vaccine |
| CN103357003A (zh) | 2006-09-07 | 2013-10-23 | 葛兰素史密丝克莱恩生物有限公司 | 疫苗 |
| US20100074918A1 (en) | 2007-05-02 | 2010-03-25 | Jan Poolman | Vaccine |
| US9610339B2 (en) | 2007-06-26 | 2017-04-04 | Glaxosmithkline Biologicals, S.A. | Vaccine comprising Streptococcus pneumoniae capsular polysaccharide conjugates |
| AU2008280799B2 (en) * | 2007-07-23 | 2013-07-11 | Sanofi Pasteur Limited | Immunogenic polypeptides and monoclonal antibodies |
| PL2271360T3 (pl) | 2008-04-16 | 2016-03-31 | Glaxosmithkline Biologicals Sa | Szczepionka |
| JP5722782B2 (ja) | 2008-09-26 | 2015-05-27 | ナノバイオ コーポレーション | ナノエマルジョン治療用組成物及びその使用方法 |
| KR101450958B1 (ko) | 2009-04-30 | 2014-10-15 | 콜레이 파마시티컬 그룹, 인코포레이티드 | 폐렴구균 백신 및 그의 용도 |
| US8668911B2 (en) | 2009-05-14 | 2014-03-11 | The Regents Of The University Of Michigan | Streptococcus vaccine compositions and methods of using the same |
| WO2010141312A2 (en) | 2009-06-01 | 2010-12-09 | Wake Forest University Health Sciences | Flagellin fusion proteins and conjugates comprising pneumococcus antigens and methods of using the same |
| ES2670576T3 (es) | 2009-09-03 | 2018-05-31 | Pfizer Vaccines Llc | Vacuna de PCSK9 |
| GB201003920D0 (en) * | 2010-03-09 | 2010-04-21 | Glaxosmithkline Biolog Sa | Method of treatment |
| GB201003924D0 (en) | 2010-03-09 | 2010-04-21 | Glaxosmithkline Biolog Sa | Immunogenic composition |
| KR101272351B1 (ko) | 2010-04-23 | 2013-06-07 | 이화여자대학교 산학협력단 | 새로운 카나마이신 화합물, 카나마이신 생산 스트렙토마이세스 속 미생물 및 카나마이신의 생산 방법 |
| WO2012131504A1 (en) | 2011-03-02 | 2012-10-04 | Pfizer Inc. | Pcsk9 vaccine |
| BR112013029514A2 (pt) | 2011-05-17 | 2019-09-24 | Glaxosmithkline Biologicals Sa | composição imunogênica, vacina, e, método de tratar ou impedir uma doença |
| US11708411B2 (en) | 2013-12-20 | 2023-07-25 | Wake Forest University Health Sciences | Methods and compositions for increasing protective antibody levels induced by pneumococcal polysaccharide vaccines |
| US11160855B2 (en) | 2014-01-21 | 2021-11-02 | Pfizer Inc. | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof |
| CA2937190A1 (en) | 2014-01-21 | 2015-07-30 | Pfizer Inc. | Streptococcus pneumoniae capsular polysaccharides and conjugates thereof |
| KR20220080201A (ko) | 2014-01-21 | 2022-06-14 | 화이자 인코포레이티드 | 접합된 캡슐 사카라이드 항원을 포함하는 면역원성 조성물 및 그의 용도 |
| BR112016015835B1 (pt) | 2014-01-21 | 2023-12-26 | Pfizer Inc | Processo de preparação de conjugados compreendendo polissacarídeos capsulares de streptococcus pneumoniae |
| ES2930318T3 (es) | 2014-02-14 | 2022-12-09 | Pfizer | Conjugados glucoproteicos inmunogénicos |
| DK3244917T5 (da) | 2015-01-15 | 2024-10-14 | Pfizer | Immunogene sammensætninger til anvendelse i pneumokokvacciner |
| KR102800419B1 (ko) | 2015-07-21 | 2025-04-25 | 화이자 인코포레이티드 | 접합된 캡슐형 사카라이드 항원을 포함하는 면역원성 조성물, 그를 포함하는 키트 및 그의 용도 |
| GB201518684D0 (en) | 2015-10-21 | 2015-12-02 | Glaxosmithkline Biolog Sa | Vaccine |
| CA3005524C (en) | 2015-11-20 | 2023-10-10 | Pfizer Inc. | Immunogenic compositions for use in pneumococcal vaccines |
| MX392525B (es) | 2017-01-20 | 2025-03-12 | Pfizer | Composiciones inmunogenicas para su uso en vacunas neumococicas |
| KR102650073B1 (ko) | 2017-01-31 | 2024-03-20 | 머크 샤프 앤드 돔 엘엘씨 | 스트렙토코커스 뉴모니아 혈청형 19f 유래의 협막 다당류 단백질 접합체의 제조 방법 |
| WO2018144439A1 (en) | 2017-01-31 | 2018-08-09 | Merck Sharp & Dohme Corp. | Methods for making polysaccharide-protein conjugates |
| AU2018225083B2 (en) | 2017-02-24 | 2023-06-01 | Merck Sharp & Dohme Llc | Pneumococcal conjugate vaccine formulations |
| PT3678654T (pt) | 2017-09-07 | 2024-08-05 | Merck Sharp & Dohme Llc | Polissacáridos pneumocócicos e sua utilização em conjugados imunogénicos de polissacárido-proteína transportadora |
| MX2020005779A (es) | 2017-12-06 | 2020-10-28 | Merck Sharp & Dohme | Composiciones que comprenden conjugados de polisacarido de streptococcus pneumoniae con proteina y metodos de uso de estos. |
| US11260119B2 (en) | 2018-08-24 | 2022-03-01 | Pfizer Inc. | Escherichia coli compositions and methods thereof |
| WO2020121159A1 (en) | 2018-12-12 | 2020-06-18 | Pfizer Inc. | Immunogenic multiple hetero-antigen polysaccharide-protein conjugates and uses thereof |
| KR20240169145A (ko) | 2018-12-19 | 2024-12-02 | 머크 샤프 앤드 돔 엘엘씨 | 스트렙토코쿠스 뉴모니아에 폴리사카라이드-단백질 접합체를 포함하는 조성물 및 그의 사용 방법 |
| JP7239509B6 (ja) | 2019-02-22 | 2023-03-28 | ファイザー・インク | 細菌多糖類を精製するための方法 |
| US20220184199A1 (en) | 2019-04-10 | 2022-06-16 | Pfizer Inc. | Immunogenic compositions comprising conjugated capsular saccharide antigens, kits comprising the same and uses thereof |
| MX2022001241A (es) | 2019-07-31 | 2022-04-20 | Sanofi Pasteur Inc | Composiciones de conjugados neumococicos multivalentes polisacarido - proteina y metodos para usar los mismos. |
| MX2022005252A (es) | 2019-11-01 | 2022-06-08 | Pfizer | Composiciones de escherichia coli y metodos de las mismas. |
| US20230085173A1 (en) | 2020-02-21 | 2023-03-16 | Pfizer Inc. | Purification of saccharides |
| CA3173729A1 (en) | 2020-02-23 | 2021-08-26 | Pfizer Inc. | Escherichia coli compositions and methods thereof |
| CA3199094A1 (en) | 2020-10-22 | 2022-04-28 | Pfizer Inc. | Methods for purifying bacterial polysaccharides |
| TW202227467A (zh) | 2020-10-27 | 2022-07-16 | 美商輝瑞大藥廠 | 大腸桿菌組合物及其方法 |
| US12138302B2 (en) | 2020-10-27 | 2024-11-12 | Pfizer Inc. | Escherichia coli compositions and methods thereof |
| EP4240410A1 (en) | 2020-11-04 | 2023-09-13 | Pfizer Inc. | Immunogenic compositions for use in pneumococcal vaccines |
| US12357681B2 (en) | 2020-12-23 | 2025-07-15 | Pfizer Inc. | E. coli FimH mutants and uses thereof |
| TW202245835A (zh) | 2021-02-04 | 2022-12-01 | 美商默沙東有限責任公司 | 用於肺炎球菌結合物疫苗之奈米乳化液佐劑組合物 |
| CA3218544A1 (en) | 2021-05-03 | 2022-11-10 | Pfizer Inc. | Vaccination against bacterial and betacoronavirus infections |
| WO2022234416A1 (en) | 2021-05-03 | 2022-11-10 | Pfizer Inc. | Vaccination against pneumoccocal and covid-19 infections |
| WO2022249107A2 (en) | 2021-05-28 | 2022-12-01 | Pfizer Inc. | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof |
| JP7714690B2 (ja) | 2021-05-28 | 2025-07-29 | ファイザー・インク | コンジュゲートさせた莢膜糖抗原を含む免疫原性組成物およびその使用 |
| MX2024008039A (es) | 2022-01-13 | 2024-07-10 | Pfizer | Composiciones inmunogenicas que comprenden antigenos de sacaridos capsulares conjugados y usos de los mismos. |
| US20250163484A1 (en) | 2022-02-25 | 2025-05-22 | Pfizer Inc. | Methods for Incorporating Azido Groups in Bacterial Capsular Polysaccharides |
| EP4522208A1 (en) | 2022-05-11 | 2025-03-19 | Pfizer Inc. | Process for producing of vaccine formulations with preservatives |
| WO2024084397A1 (en) | 2022-10-19 | 2024-04-25 | Pfizer Inc. | Vaccination against pneumoccocal and covid-19 infections |
| WO2024110827A1 (en) | 2022-11-21 | 2024-05-30 | Pfizer Inc. | Methods for preparing conjugated capsular saccharide antigens and uses thereof |
| IL321062A (en) | 2022-11-22 | 2025-07-01 | Pfizer | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof |
| IL321069A (en) | 2022-12-01 | 2025-07-01 | Pfizer | Pneumococcal conjugate vaccine preparations |
| WO2024166008A1 (en) | 2023-02-10 | 2024-08-15 | Pfizer Inc. | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof |
| AU2024246082A1 (en) | 2023-03-30 | 2025-10-16 | Pfizer Inc. | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof |
| CN121057590A (zh) | 2023-04-14 | 2025-12-02 | 辉瑞公司 | 包含缀合荚膜糖抗原的免疫原性组合物及其用途 |
| WO2024224266A1 (en) | 2023-04-24 | 2024-10-31 | Pfizer Inc. | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof |
| TW202500153A (zh) | 2023-05-18 | 2025-01-01 | 美商默沙東有限責任公司 | 用於肺炎鏈球菌疫苗之化合物及佐劑調配物 |
| WO2024241172A2 (en) | 2023-05-19 | 2024-11-28 | Glaxosmithkline Biologicals Sa | Methods for eliciting an immune response to respiratory syncycial virus and streptococcus pneumoniae infection |
| TW202527906A (zh) | 2023-09-14 | 2025-07-16 | 美商輝瑞股份有限公司 | 包含經結合之肺炎鏈球菌莢膜醣抗原之佐劑化致免疫性組成物及其用途 |
| US20250161420A1 (en) | 2023-11-16 | 2025-05-22 | Merck Sharp & Dohme Llc | Peptide conjugate vaccine compositions and methods for the treatment of alzheimer's disease |
| WO2025133971A1 (en) | 2023-12-23 | 2025-06-26 | Pfizer Inc. | Improved methods for producing bacterial capsular saccharide glycoconjugates |
| WO2025186705A2 (en) | 2024-03-06 | 2025-09-12 | Pfizer Inc. | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof |
| WO2025191415A1 (en) | 2024-03-11 | 2025-09-18 | Pfizer Inc. | Immunogenic compositions comprising conjugated escherichia coli saccharides and uses thereof |
| WO2025219904A1 (en) | 2024-04-19 | 2025-10-23 | Pfizer Inc. | Improved methods for producing glycoconjugates by reductive amination in aprotic solvent |
| WO2025219908A2 (en) | 2024-04-19 | 2025-10-23 | Pfizer Inc. | Media and fermentation methods for polysaccharide production in bacterial cell culture |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4425437A (en) | 1979-11-05 | 1984-01-10 | Genentech, Inc. | Microbial polypeptide expression vehicle |
| US4431739A (en) | 1979-11-05 | 1984-02-14 | Genentech, Inc. | Transformant bacterial culture capable of expressing heterologous protein |
| US4338397A (en) | 1980-04-11 | 1982-07-06 | President And Fellows Of Harvard College | Mature protein synthesis |
| US5866135A (en) * | 1994-04-21 | 1999-02-02 | North American Vaccine, Inc. | Group A streptococcal polysaccharide immunogenic compositions and methods |
| CZ327897A3 (cs) * | 1995-06-07 | 1998-02-18 | Alberta Research Council | Imunogenní a imunostimulační oligosacharidové kompozice, způsoby jejich přípravy a použití |
| WO1998018931A2 (en) * | 1996-10-31 | 1998-05-07 | Human Genome Sciences, Inc. | Streptococcus pneumoniae polynucleotides and sequences |
| JP2001517449A (ja) * | 1997-09-24 | 2001-10-09 | リージェンツ・オブ・ザ・ユニバーシティ・オブ・ミネソタ | ストレプトコッカス・ニューモニア由来のヒト補体ｃ３分解プロテイナーゼ |
| JP2002531055A (ja) * | 1998-07-27 | 2002-09-24 | マイクロビアル テクニクス リミティッド | 肺炎連鎖球菌のタンパク質及び核酸分子 |
| CA2340692A1 (en) * | 1998-08-19 | 2000-03-02 | North American Vaccine, Inc. | Immunogenic .beta.-propionamido-linked polysaccharide protein conjugate useful as a vaccine produced using an n-acryloylated polysaccharide |
| EP1115875A1 (en) * | 1998-09-24 | 2001-07-18 | Regents Of The University Of Minnesota | Human complement c3-degrading polypeptide from streptococcus pneumoniae |
| DK1140157T3 (da) | 1998-12-21 | 2009-06-08 | Medimmune Inc | Streptococcus pneumoniae-proteiner og immunogene fragmenter til vacciner |
| ATE394489T1 (de) | 1998-12-23 | 2008-05-15 | Id Biomedical Corp | Streptococcus antigene |
-
2001
- 2001-06-19 EA EA200201280A patent/EA006232B1/ru not_active IP Right Cessation
- 2001-06-19 JP JP2002504289A patent/JP5051959B2/ja not_active Expired - Fee Related
- 2001-06-19 CN CN200710181645.XA patent/CN101260149B/zh not_active Expired - Fee Related
- 2001-06-19 TR TR2007/04553T patent/TR200704553T2/xx unknown
- 2001-06-19 KR KR1020027017453A patent/KR100927767B1/ko not_active Expired - Fee Related
- 2001-06-19 EP EP01949136A patent/EP1303612A2/en not_active Withdrawn
- 2001-06-19 HU HU0301656A patent/HU228706B1/hu not_active IP Right Cessation
- 2001-06-19 CN CN01814388A patent/CN1449446A/zh active Pending
- 2001-06-19 CA CA2413450A patent/CA2413450C/en not_active Expired - Fee Related
- 2001-06-19 PL PL360413A patent/PL214229B1/pl unknown
- 2001-06-19 EP EP10179497A patent/EP2281891A3/en not_active Withdrawn
- 2001-06-19 MX MXPA03000103A patent/MXPA03000103A/es active IP Right Grant
- 2001-06-19 AU AU7038101A patent/AU7038101A/xx not_active Withdrawn
- 2001-06-19 AU AU2001270381A patent/AU2001270381B2/en not_active Ceased
- 2001-06-19 NZ NZ553554A patent/NZ553554A/en not_active IP Right Cessation
- 2001-06-19 WO PCT/CA2001/000908 patent/WO2001098334A2/en not_active Ceased
- 2001-06-19 IL IL15355801A patent/IL153558A0/xx unknown
- 2001-06-19 CZ CZ2003154A patent/CZ2003154A3/cs unknown
- 2001-06-20 AR ARP010102945A patent/AR033980A1/es not_active Application Discontinuation
- 2001-06-20 UY UY26783A patent/UY26783A1/es not_active Application Discontinuation
-
2002
- 2002-12-19 IL IL153558A patent/IL153558A/en not_active IP Right Cessation
- 2002-12-19 NO NO20026121A patent/NO331103B1/no not_active IP Right Cessation
-
2012
- 2012-05-23 JP JP2012117846A patent/JP5889103B2/ja not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TR200704553T2 (tr) | Streptokok antijenleri. | |
| NZ512574A (en) | Novel streptococcus antigens useful as vaccines | |
| AP2000001886A0 (en) | Group B streptococcus antigens. | |
| ATE325620T1 (de) | Streptococcus pneumoniae proteine und impfstoffe | |
| ATE198051T1 (de) | Pneumokokken-polysaccharid-rekombinante- pneumolysin-konjugate als impfstoffe für die immunisierung gegen pneumokokken-infektionen | |
| ATE317013T1 (de) | Antigen omp26 aus haemophilus influenzae | |
| BR0208874A (pt) | Proteìnas superficiais de streptococcus pyogenes | |
| WO2001081380A3 (en) | Immunogenic pneumococcal protein and vaccine compositions thereof | |
| UY26763A1 (es) | Inmunización del ganado lacteo con proteína gapc quimérica contra infección por estreptococo. | |
| WO2001096381A3 (en) | IMMUNIZATION OF DAIRY CATTLE WITH GapC PROTEIN AGAINST STREPTOCOCCUS INFECTION | |
| DE60234772D1 (de) | Gruppe-b streptococcus antigene und entsprechende dna-fragmente | |
| ATE547527T1 (de) | Gruppe b streptococcus bvh-a2 und bvh-a3 antigene | |
| EP1950302A3 (en) | Streptococcus antigens | |
| BR0111886A (pt) | Antìgeno para estreptococos | |
| EP1219635A3 (en) | Chlamydia pneumoniae antigenes | |
| DE60031106D1 (de) | Fluordesoxyuridin-resistente streptococcus gordonii stämme | |
| EP1734050A3 (en) | Immunization of dairy cattle with GapC protein against streptococcus infection |